PDC and anemia (phenotype): Small-molecule PHD inhibitors have shown nontoxic therapeutic utility: roxadustat and daprodustat (Dap), inter alia, stimulate erythropoietin production in a HIF-α-dependent manner to enhance erythropoiesis for anemia treatment in patients with chronic renal failure (reviewed previously8).